Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272180 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
A Phase 2 study of Invasive Meningococcal Disease, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 484
- Enrollment target
- 13
- Study locations
NCT01272180 is a Phase 2 study of Invasive Meningococcal Disease that has completed, run by Novartis Vaccines. The registered enrollment target is 484 participants. The trial reports 13 study locations across 6 states.
The verdict
NCT01272180, a Phase 2 study of Invasive Meningococcal Disease, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 484 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines
Conditions Studied
Interventions
- BIOLOGICAL Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.
- BIOLOGICAL Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
- BIOLOGICAL Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
- BIOLOGICAL Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Study Locations (13)
Other
- Specjalistyczna Przychodnia Lekarska Internistyczno-Pediatryczna,,Juniperus"s.c, ul.Kościuszki 41 - Izabelin (Warszawa)
- NZOZ HIPOKRATES II.sp.zo.o, ul.Pachonskiego 12 - Krakow
- NZOZ PRAKTIMED Sp.zo.o, ul.Strzelców 15 - Krakow
- Klinika Pediatrii Centrum Medycznego Kształcenia PodyplomowegoSzpital Bielański, ul. Cegłowska 80 - Warsaw
- Katedra i Klinika Pediatrii i Chorób Infekcyjnych, ul.O.Bujwida 44 - Wroclaw
California
- Madera Family Medical Group,1111 West 4th Street - Madera
- Center for Clinical Trials LLC, 16660 Paramount Blvd, Suite 301 - Paramount
Kentucky
- Kentucky Pediatric/Adult Research, 201 south 5th street - Bardstown
- Bluegrass Clinical Research Inc.5512 Bardstown Road, Suite 2 - Louisville
Ohio
- Ohio Pediatric Research Association, 7371 Brandt Pike, Suite C - Huber Heights
- Ohio Pediatric Research Association, 1775 Delco Park Drive - Kettering
Alabama
- Alabama Clinical Therapeutics, 806 St. Vincent's Drive, Suite 615 - Birmingham
Tennessee
- Focus Research Group,201 Signature Place - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01272180
The ClinicalTrials.gov registry entry for NCT01272180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Invasive Meningococcal Disease appearing as the primary indexed condition, and to 4 interventions - of which Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. is the first listed.
NCT01272180 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01272180 about?
NCT01272180 is a clinical study titled "Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults". This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines
What is the current status of trial NCT01272180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 484 participants. The study started on 2011-08. Estimated completion is 2012-09.
What conditions does trial NCT01272180 study?
This clinical trial studies the following conditions: Invasive Meningococcal Disease.
What interventions are being tested in trial NCT01272180?
The interventions under investigation include: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. (BIOLOGICAL), Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. (BIOLOGICAL), Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. (BIOLOGICAL), Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV. (BIOLOGICAL).
Who is sponsoring clinical trial NCT01272180?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01272180 being conducted?
This trial has 13 study locations across Alabama, California, Kentucky, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.